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ABSTRACT 
The purpose of this independent study is to review the viral and 
immunologic factors in human immunodeficiency virus (HIV) infection and 
present the clinical manifestations most commonly associated with acquired 
immune deficiency syndrome (AIDS). As physical therapists, we will thus 
increase our knowledge base of this complex disease and understand the many 
opportunistic infections associated with HIV infection and the various aspects of 
AIDS. In addition, by having a better understanding of the disease, we may 
overcome our fears, improve our personal attitudes toward patients with 
HIV/AIDS, and improve and prolong the quality of life of individuals with the 
disease. 
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CHAPTER I 
INTRODUCTION AND METHODOLOGY 
No disease in modern time has had quite the impact on the civilized 
world as had acquired immunodeficiency syndrome (AIDS). In January 1992, 
the Centers for Disease Control (CDC) reported over one million Americans 
infected with the human immunodeficiency syndrome (HIV), 206,392 diagnosed 
with AIDS, and 133,232 having died from the disease. 1 AIDS is already a 
leading killer of men and women 15 to 44 years old in our country.2 The scope 
of the HIV/AIDS pandemic is even more dramatic world wide. The World 
Health Organization (WHO) has estimated cumulative global total of HIV-
infected adults and children as of 30 June 1993 is about 13 million, which 
means that, for the world population, one in every 250 adults has been infected 
with HIV.3 WHO estimates that over 2.5 million cumulative AIDS cases have 
occurred to date, whereas over 50% of reported AIDS cases are from 
developed countries, about 80% of all estimated AIDS cases are from the 
developing world.4 Although the outlook in the near future is promising for 
curative treatment or effective vaccine, the National Commission of AIDS states 
"even if a cure were found tomorrow the sequelae of the disease would still 
affect our communities for 10 to 15 more years. ,,5 
1 
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Amid the social and political upheaval precipitated by the HIV/AIDS 
pandemic, a critical problem has silently but steadily emerged: Who is to 
provide care for the increasing numbers of afflicted individuals? There is a 
demanding need for more professionals to become active in both prevention 
and treatment of the HIV disease. Although few practitioners have denied their 
responsibility to provide care, there is a reluctance on the part of some to 
actively participate. Caring for those with HIV infection entails a risk. There is 
little doubt that the consequences of contracting AIDS are very grave, and it 
understandable that health care workers, physical therapist among them, may 
experience intense anxiety and fear. 
The purpose of this independent study is to review the biology and 
epidemiology of HIV infection and the most common clinical manifestations of 
the virus. The study will allow the physical therapist an opportunity to 
understand the disease process and make an important contribution to people 
with HIV in all disease stages--acute, chronic, and terminal. 
The methodology employed a review of existing literature, beginning with 
a Med-lin computer search. Other sources reviewed included textbook 
materials, government reports, and a personal interview with an HIV/AIDS 
individual. 
CHAPTER II 
HISTORY AND EPIDEMIOLOGY 
Although misunderstanding, fear, and discrimination still surround HIV 
and AIDS, much has been learned. The earliest known case of death from 
AIDS occurred in 1959.6 A paper published in Lancet, 1990, states the human 
immunodeficiency virus was found in the tissues of a 25-year-old seaman from 
northwestern part of Manchester, England who died of pneumonia in 1959.6 
The seaman's wife and three youngest daughters appear to also have been 
infected, as they died of similar symptoms some years later. Other early cases 
of HIV infection were in three members of a Norwegian family who developed 
AIDS in the 1960s and died in 1976.6 Antibodies to the virus were found in the 
blood of an individual from Zaire, Africa also in 1959, but it is not known if the 
patient died from AIDS.6 From analysis of the infection rates in Africa, it is 
thought that HIV has existed in Africa for 30 to 40 years.6 
The most prominent theory of how the virus started follows. In the 1950s 
American doctors were testing a vaccine intended to wipe out the polio virus; 
the vaccine was contaminated by the simian immunodeficiency virus (SIV).? 
The contaminated polio vaccine was administered to at least 325,000 Central 
Africans; it is hypothesized that after a series of mutations in humans, the virus 
3 
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established itself into its present deadly form.? The SIV is from a family of 
relatively harmless primate retroviruses that is endemic in green monkeys of 
equatorial Africa and closely related to the AIDS virus.8 
The epidemiology of HIV has become clearer and has been discussed by 
a number of authorities in the United States. The Center for Disease Control 
(CDC) has led the epidemiological investigation of AIDS. The disease that 
became known as acquired immunodeficiency syndrome (AIDS) was first 
reported in a 1981 Morbidity and Mortality Weekly Report, published by the 
CDC.9 In 1983, scientists working at the Pasteur Institute, Paris, isolated a 
retrovirus from the lymph node of person with AIDS-related symptoms.10 In 
1985, epidemiologic and virologic studies confirmed a ribonucleicacid (RNA) 
retrovirus as human immunodeficiency virus (HIV) and confirmed HIV as the 
causal agent associated with the development of AIDS. 10 HIV-1, a retrovirus, is 
related to a family of lentiviruses that generally cause chronic, indolent 
infections characterized by a long clinical latency period, nervous system 
involvement, and persistent viremia. 11 
CHAPTER III 
BIOLOGY 
Pathogenesis 
The cellular events and reactions of HIV infection have become clearer 
and have been discussed by a number of authorities in the United States. 12-14 
The causative agent of HIV is now known to be one of the human retrovirus 
that selectively infects CD4 lymphocytes and monocyte/macrophages.15 The 
structure, genetic composition, and major proteins of HIV have been identified, 
and its basic pathophysiology defined. This chapter will cover the more 
important features of the pathologic mechanisms occurring in the development 
of the HIV disease. 
Viruses are packets of infectious nucleic acid surrounded by protective 
coats. In a virion, the viral nucleic acid is covered by a protein capsid, which 
protects it from enzymatic attack and mechanical breakage and delivers it to a 
susceptible host.16 The capsid itself is surrounded by an envelope containing 
membrane lipids and glycoproteins. The HIV virion (Figure 1) is enveloped by a 
lipid bilayer membrane containing two glycoproteins: gp41 and gp120.16-18 The 
external envelope protein (gp120) is associated with small protrusions or spikes 
on the outer surface of the virion and is attached to the viral capsid via 
5 
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Figure 1. Structure and genetic composition of HIV. (Courtesy of Jon Fuller, MD, Boston City 
Hospital) 
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the transmembrane protein, gp41.19 The glycoprotein gp41 spans the 
membrane and is disulfide-bonded to gp120, which is located on the external 
face. 16-19 
Retroviruses are enveloped and possess a single strand of ribonucleic 
acid (RNA).20 All are characterized by their ability to serve as a template for 
production of deoxyribonucleic acid (DNA) in host target celis.16,18,19 This 
reverse transcription is accomplished through possession of an enzyme. 
Reverse transcriptase, a DNA polymerase, translates a single strand of RNA 
into a double-stranded DNA copy.16,18-20 An additional viral enzyme, an 
endonuclease, incorporates this DNA copy into the chromosomal structure of 
the target cell as a provirus.21 
HIV Structure and Genetic Composition 
HIV is composed of a central cylindrical core of diploid (two 
chromosomes) RNA surrounded by a spherical lipid envelope.22 The viral 
genome (DNA and RNA) consists of three structural components: pol, gag, and 
env (Figure 1) which are essential for productive infection.18,23.24 The gag gene 
(proteins) make up the core and the phosphoproteins that are found inside the 
nucleoid. The protein gag codes for p24, which is found in the core and 
surrounds the viral RNA. Gag or p24 also codes for other proteins, including 
p17, p9, and p7.16.19.21 p24 is measurable in the serum and serves as a marker 
for viral replication.16,19.21 Pol codes for the reverse transcriptase (RNA-directed 
DNA polymerase), which is responsible for the production of both the DNA 
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polymerase and endonuclease located in the viral core.16.21 The env gene 
products include two glycoproteins that are part of the viral envelope: gp120 
and gp41. Both proteins appear to be important for the recognition and 
attachment of HIV to its CD4 lymphocyte target cel1.24,25 These genes are 
located between long terminal repeat (Itr) segments. L TRs carry multiple 
signals--enhancers, promoters, and polyadenlylation sites--for the expression of 
retroviral genes.16 
HIV also possesses genes that code for proteins having important 
regulatory functions. 24,26 The tat (transactivator) gene is responsible for 
production of a protein that enhances viral replication through its interaction with 
long terminal repeats at either end of the genome. Rev (regulator of 
expression) of virion proteins codes for the mechanism that results in the 
discontinuation of regulatory protein production and increased production of 
structural proteins. Vif (virion infectivity factor) codes for a protein that appears 
important for the budding of viral progeny from the surface of the host cells and 
their subsequent infectivity. 
Pathophysiology of HIV Infection 
The pathophysiology of HIV relates to its ability to infect human cells that 
possess CD4 membrane receptors. The host cell for HIV is the T4 lymphocyte, 
a vital contributor to the immune response; this lymphocyte was named for an 
antigen present on its surface. Major target cells include monocytes, 
macrophages, and their hematologic precursors.27 Other cell types, including 
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Langerhan's cells of the skin, epithelial gut cells, and uterine cervical cells, have 
also been identified as harboring HIV infection.21 
CD4 receptors have a binding site capable of interacting with two 
envelope proteins that are a part of the viral envelope. These include gp41 , the 
transmembrane protein, and gp120 which protrudes from the envelope (Figure 
2) and is closely associated with but not covalently linked to gp41.18,22 Through 
this proposed mechanism for HIV infection of a cell, the outside viral envelope 
protein, gp120, attaches to a cell surface receptor, most likely the CD4 antigen. 
The external portion of the transmembrane protein, gp41, attaches to a 
proposed specific fusion receptor on the cell surface. Either receptor may 
permit viral entry into the cell, but both together would make this event more 
efficient.16,21 Once the virus is within the cytoplasm of the host cell, the 
envelope of the virus is shed, and its contents are released.16,21 It is then that 
reverse transcription occurs: a double-stranded DNA is made from the viral 
RNA template. Newly created viral DNA can exist in either free form or it can 
be integrated through the action of an endonuclease and go into the cellular 
DNA as a provirus.21 ,28 
Infected cells remain in a dormant state for a variable period of time and 
thus elude the host immune system possibly for years, a potential reason for 
long incubation periods.27,28 When activations occur, the proviral DNA 
transcribes genomic and messenger RNA, leading to release of infectious 
progeny.21,29 After viral proteins are synthesized, new virions are assembled 
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Figure 2. HIV/CD4lymphocyte interaction. (Courtesy of Jon Fuller, MD, Boston City Hospital) 
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that bud from the infected cell and circulate until they identify new target 
cells.21 ,29 These infected cells can then spread the virus through production of 
infectious progeny or by fusion with uninfected cells.30 This latter cell-to-cell 
interaction is important because it permits the transfer of viral information into 
an uninfected cell and avoids exposure of the newly formed viruses to 
neutralizing antibodies.21 ,28,29 
The initial studies of the AIDS virus revealed its presence in peripheral 
blood cells, particularly T-helper lymphocytes.31 -33 Subsequently, HIV was 
recovered from macrophages and was shown to infect a variety of other human 
cells, including B lymphocytes, promyelocytes, fibroblast, and epidermal 
Langerhans cells.34-37 Therefore, the presence of the CD4 receptor appears to 
explain the susceptibility of many cells to HIV. Monocytes and macrophages 
serve an important role in the pathogenesis of HIV infection.38 Once infected, 
they appear to be tolerant of viral replication, surviving to disseminate virus to a 
variety of body sites. Thus, these cells serve as an important source of 
immunologically protected new virus.21 It is generally accepted that monocyte 
and macrophage function appears to be compromised to some degree by HIV 
infection, contributing further to immunosuppression. 
HIV affects the central nervous system (CNS) in a complex and 
incompletely understood manner. It is thought that the HIV infected 
macrophages probably carry the virus into the CNS across the blood-brain 
barrier (Figure 3) by means of a "Trojan Horse" mechanism.18,21 ,39 Once the 
12 
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Figure 3. "Trojan horse" mechanism of central nervous system infection. (Courtesy of Jon 
Fuller, MD, Boston City Hospital) 
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virus gains access to the CNS, neurologic damage is likely to occur through 
several different mechanisms.21 Although HIV does not directly infect neurons 
(Figure 4), infected macrophages may release toxic cytokines that are injurious 
to neurons "innocent bystander mechanism.,,18,21,40 In addition, freely circulating 
gp120 may result in neuronal damage by affecting the integrity of the blood 
vessels supplying the nutrition or by interfering with normal calcium channel 
function. 18,21,28,38,39 
Response to HIV Infection and Stages of Infection 
HIV infection elicits both cell-mediated and humoral immune responses 
from the host.41 Soon after infection with HIV, there is a brief period of intense 
viral replication. During this time the patient is asymptomatic, but serologic 
testing reveals a rise in titer of p24 antigen during the humoral response.21 The 
majority of individuals notice very few, if any, symptoms associated with 
seroconversion. An estimated 40% to 60% of individuals will develop 
symptoms of an acute mononucleosis-like syndrome, consisting of sore throat, 
headache, fever, myalgias, lymphadenopathy, and skin rash.42-44 
The cellular immune response involves a decrease in absolute numbers 
of CD4 lymphocytes with increase duration of infection.45 This drop is usually 
gradual for a prolonged period (clinical latency phase), with a more rapid 
decline associated with the onset of symptoms later in the course of the 
disease. The COB lymphocyte count generally increases early in HIV infection, 
and together with macrophages may act in concert to interfere with viral 
14 
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Figure 4. "Innocent bystander" mechanism of central nervous system infection. (Courtesy of 
Jon Fuller, MD, Boston City Hospital) 
15 
replication by production of a diffusible factor or by directly killing infected 
cells.18,21,39,40 However, HIV infection is a chronic disease and in the end-stage 
both CD4 and CD8 cell lines become depleted. The loss of CD4 lymphocyte 
cells are associated with the development of the characteristic opportunistic 
infections and malignancies of AIDS. Thus the measurement of CD4-positive 
lymphocytes is one of the most important determinants for clinically staging the 
disease status of HIV-infected patients. The absolute CD4 count cannot be 
measured directly but is calculated by the following formula:28 
Absolute Total Percent Percent 
CD4 = White Blood X Lymphocytes X CD4 
Count Count Cells 
Normal values for CD4 counts are generally 800 to 1200 cells/mm3 in adults, 
with fluctuations of as much as a 150 to 300 cell/mm3 difference between 
morning and evening values in normal adult hosts.28,46 Asymptomatic-
lymphadenopathy may occur when the CD4 count drops below 800 cells/mm3. 
When the CD4 cell count drops below 500 cells/mm3, prophylaxis therapy is 
recommended in response to immune dysfunction and/or to secondary 
infections caused by opportunistic infections.46 
HIV is characterized by evolving clinical and serological manifestations 
identified as predictors of HIV disease progression and the rate at which AIDS 
develops. The clinical manifestations usually depend on the stage of infection. 
Whether it is early infection with little immune dysfunction, or whether the 
infection has been present long enough to cause moderate or severe immune 
16 
impairment, HIV is a slowly progressive disease. A classification system for 
these stages has been developed by the Center for Disease Control (Table 1 ).47 
Group 1. 
Group 2. 
Group 3. 
Group 4. 
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Table 1. CDC Classification of HIV Infection. 
Initial infection. 
Asymptomatic carriers. 
Persistent generalized adenopathy. 
AIDS and AIDS-related complex 
Subgroup 4A. 
Constitutional symptoms 
Subgroup 48. 
Neurologic disease 
Subgroup 4C. 
Secondary infectious disease 
Category 1 and 2 
Various opportunistic infections 
Subgroup 4D. 
Secondary malignancies 
Subgroup 4E. 
Other AIDS-related conditions 
National Institute of Mental Health, 1991. 
CHAPTER IV 
FUNCTIONAL AND CLINICAL MANIFESTATIONS 
The immune system is complex, with many types of defenses against 
infections. Understanding the effects of the HIV virus on the human immune 
system is the key to understanding the clinical problems of HIV patients. HIV 
infection is a highly lethal condition, with an average length of time from initial 
infection to development of AIDS of approximately 10 years and a survival time 
from the diagnosis of AIDS to death of approximately two to five years.48,49 HIV 
is also known as a chronic disease with a fairly predictable pattern of evolution 
and clinical manifestations. A physical therapist may treat a person with 
HIV/AIDS who has several related conditions or opportunistic diseases. When 
the person with AIDS develops secondary neurologic, musculoskeletal, or 
cardiopulmonary complications the therapist provides physical therapy 
evaluation and treatment. It is important that the physical therapist obtains 
baseline data about the patient's state of being, state of fitness, and general 
strength. Table 2 is a summary of the common HIV signs and symptoms, and 
their possible causes of the HIV disease are presented.21 ,28,46 
18 
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Table 2. Common Manifestations of HIV Disease 
Signs and Symptoms 
SYSTEMIC 
Weight loss 
Tiredness 
Fever and 
night sweats 
DERMATOLOGIC 
Discoloration 
Rash 
ORAL 
White patches 
VISUAL 
Visual field 
optic 
FUNDOSCOPIC 
Retinal hemorrhage 
Retinal infiltrates 
Possible Causes 
AIDS-related wasting syndrome, enteropathy, 
depression 
Wasting syndrome, anemia, opportunistic 
infection 
Primary HIV infection, TB, MAl, lymphoma 
Kaposi's sarcoma, tinea corporis, basal cell 
carcinoma 
Herpes zoster or simplex, psoriasis, 
molluscum contagiosum, pustular 
folliculitis, seborrhea, impetigo, drug 
reaction 
Oral candidiasis, hairy leukoplakia, Herpes 
simplex, cytomegalovirus, Kaposi' 
sarcoma, aphthous ulcers 
CMV or toxoplasma retinitis, syphilitic 
defects neuritis, progress multifocal 
leukoencephalopathy (PML) 
CMV retinitis 
Benign HIV disease, CMV, toxoplasma 
retinitis 
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Table 2 (cont.) Common Manifestations of HIV Disease 
Signs and Symptoms 
LYMPH NODES 
Lymphadenopathy 
CARDIOPULMONARY 
Cough, dyspnea, 
SOB, tachypnea 
HEMATOLOGIC 
Easy bruisi ng, 
bleeding 
GASTROINTESTINAL 
Diarrhea 
Organomegaly 
Anal pain or ulcer 
GENITOURINARY 
Genital lesions 
NEUROLOGIC 
Headache 
Possible Causes 
AIDS-related lymphadenopathy, TB, KS 
syphilis, lymphoma, bacterial or viral 
infection 
Pneumocystis pneumonia, TB, bacterial 
fungal, or viral pneumonia, 
myocarditis, cardiomyopathy 
Idiopathic thrombocytopenic purura, 
drug reaction, Kaposi's sarcoma 
Bacterial or parasitic infection, CMV, KS, 
HIV-related enteropathy, food intolerance 
Lymphoma, TB, tumor, fungal infection 
(histoplasmosis), MAl 
HSV, sarcoma, CMV, Abscess 
Primary syphilis, HSV, chancroid, psoriasis, 
papillomavirus 
CNS toxoplasmosis, lymphoma, TB 
meningitis or cryptococcal, PML 
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Table 2 (cont.) Common Manifestations of HIV Disease 
Signs and Symptoms 
Memory or thought 
deficits 
Nu mbness/dysesthesia 
Ataxia 
Seizures 
Possible Causes 
AIDS encephalopathy, meningitis, PML, 
metabolic abnormalities, other organic 
disorders 
Herpes Zoster, neuropathy, myelopathy 
CNS toxoplasmosis, lymphoma, PML, 
syphilis, neuropathy, visual defect 
CNS toxoplasmosis, PML, CNS lymphoma, 
meningitis, encephalitis 
22 
Indicators of HIV Infection 
In response to a growing awareness of the many manifestations of HIV 
infection, the CDC has changed the definition of AIDS to include 
encephalopathy, wasting syndrome, a CD4 count <200 cells/mm3, invasive 
cervical cancer, recurrent pneumonia, and pulmonary tuberculosis.46,5o 
Neuropsychiatric Aspects of HIV Infection 
The neuropsychiatric aspects of HIV infection present challenges for all 
health-care workers. HIV infects the body and brain, and it always affects the 
mind. Physical therapists will be increasingly faced with interpreting and 
integrating the impact of HIV on a person's central nervous system function. 
This section presents the neuropsychiatric manifestations of HIV-related 
disorders that are relevant to physical therapy treatment concerns. Many of the 
functional and organically based CNS disorders often affect the mental 
capacity, the quality of life, and the maintenance of autonomous function and 
independent living. 
Many HIV-infected patients will have "mental symptoms" before they 
develop the better known opportunistic infections. Patients may complain early 
on of forgetfulness, mental slowing, social withdrawal, avoidance of complex 
tasks, and personality changes.51 Inattentiveness, inability to concentrate, 
distractibility, and apathy may be subtle, and HIV patients may have 
accommodated slowly to changes without realizing it.51 
23 
Dementia (subacute encephalitis, neurocognitive syndrome) is defined as 
a complex of cognitive, motor, behavioral and affective abnormalities. 
Impairment in some or all of these four categories of function may be present at 
any time during the course of HIV disease.52,53 People with HIV-infection may 
continue to have these mild deficits, which are differentially disabling depending 
on the patient's work or living situation, for long periods, without necessarily 
progressing to further impairment.54 Others progress fairly rapidly from these 
signs to more disabling motor brain dysfunctions such as dysgraphia, 
dysarthria, hyperreflexia, spasticity, incontinence, ataxia, mutism, aphasia, 
myoclonus and seizures.54 What is especially alarming to patients with HIV-
related neurocognitive decline is that unlike the patient with Alzheimer's 
disease, the HIV person will retain intellectual function and consciousness of 
the self until quite late in the disease process.54 
Delirium is reported as one of the most common psychiatric diagnoses 
among hospitalized, severely ill AIDS patients.55 Delirium in the HIV-infected 
patient may result from secondary opportunistic infections and neoplasms.54 
Delirium is defined by DSM-IIIR with the general criteria as rambling, irrelevant, 
or incoherent speech; illusions, hallucinations, disorientation to time, place, or 
person; and reduced ability to maintain attention to external stimuli.56 
Organic mood disorders are expressed commonly as grandiose ideation, 
delusions, mood swings, irritability, and personality changes. These symptoms 
are pathologic changes in the limbic system that may be caused by HIV 
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infection.57•58 Adjustment disorders in HIV patients most common are anxiety 
and depression. Studies suggest that a depressive syndrome may be the 
precursor for the onset of a CNS infection and considered a reaction to HIV 
illness.59•6o 
Fatigue may be the presenting complaint of an underlying depression 
early in the course of HIV infection. In later stages of HIV infection, fatigue may 
be the result of chronic disease and is often perceived as untreatable.54.57 As 
physical therapists, helping patients to learn about their energy levels and 
proportioning their energy according to tasks is essential. 
Because the HIV epidemic is still relatively new, only a few related 
disability studies exist in the literature. Common problems among patients who 
were referred consecutively to a rehabilitation service included generalized 
deconditioning (27%) and neurologic dysfunction (45%)? Functional problems 
included impaired mobility (76%), difficulty with self-care (57%), impaired 
cognition (29%), and uncontrolled pain (37%)? 
A more specific study documented the types and degrees of disability 
found in persons with AIDS at discharge from acute care hospitalization, based 
on the Functional Independence Measure (FIM).62 The FIM was developed by 
the State University of New York, that covers 18 functional areas in self care, 
mobility, communication, and social cognition; eating; grooming; bathing; 
dressing (upper body); dressing (lower body); toileting, bladder management; 
bowel management; bed, chair, and wheelchair transfer; toilet transfer; tub or 
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shower transfer or both; walking or wheelchair locomotion; stair climbing; 
comprehension; expression; social interaction; problem solving; and memory.63 
Of the sample population, at least 60% required human assistance in one of the 
18 functional areas; 32% in five or more areas.63 Approximately 51 % required 
human assistance in stair climbing; 38% in ambulation; 33% in eating and 
bathing; and 25% in transferring to the bathtub or shower.63 These daily living 
skills were further compounded by the loss of self-esteem, loss of community, 
and often differentiation pain resulting from partial or complete damage to 
afferent nerve pathways toward the central nervous system.63,64 
Neurological Complications of HIV Infection 
Although the loss of active daily living skills, psychiatric disorders, loss of 
physical independence, and other problems are experienced, the most 
significant disability faced by patients with HIV may be pain. The type of pain 
depends on the disease process that is secondary to the HIV infection. 
Potential etiologies of pain among patients with HIV include a wide variety of 
rheumatologic, dermatologic, and musculoskeletal changes resulting from HIV-
related myopathy and muscle wasting syndrome.63,65 
The etiologies of pain consists of chest pain related to pneumocystis 
carinii pneumonia (PCP); abdominal pain from (HIV-related lymphadenopathy, 
Kaposi's sarcoma, infectious diarrhea, organomegaly, ileus, and nonspecific 
gastritis); headache pain due to toxoplasmosis, CNS lymphoma, cryptococcus 
meningitis; midsternal burning or dysphagia from herpes simplex, 
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cytomegalovirus, candidiasis, infection; and low back pain may result from 
malignant lymphomas.63,65-67 These neurologic complications may evolve 
acutely, during the asymptomatic phase, or during late nervous system 
involvement by the HIV infection. 
Additional neurological complications in the 200 to 500 CD4 cell/mm3 
count may result in meningitis, ataxia, myelopathy, cranial neuropathy (CN V, 
VII, VIII), and brachial plexopathy.68 During the latent phase of HIV infection a 
demyelinating neuropathy that resembles Guillain-Barre' syndrome and a 
multiple sclerosis-like illness have been reported.69-71 
It has been estimated that up to 80% of all persons with HIV will have 
some type of CNS or peripheral nervous system (PNS) involvement prior to 
death.72 PNS dysfunction among patients with HIV may have multiple etiologies 
in addition to the HIV infection itself, including malnutrition, immobility, 
opportunistic infections, wasting syndrome, and drug toxicities. 
Distal symmetric polyneuropathy (DSPN) is one of the most common 
forms of neuropathy in patients with AIDS. DSPN may be described as a 
progressive, painful neuropathy with prominent dysesthesia and areflexia with or 
without mild muscle weakness.73 Dysesthesias may be burning and constant. 
The patient may report numbness or tingling in the toes that spread proximally; 
later there may be finger and upper extremity involvement.54,57,66,73 Tropic 
changes may occur in distal areas of the skin, and muscle weakness varies; 
generally it is mild, affecting the intrinsic foot muscles.54,57,64,73 Distal reflexes 
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are hypoactive or absent but may be present at the knees or in the upper 
extremities.54,64,73 Sensory dysfunction is usually moderately impaired.54,64,73 
Pathological studies suggest a retrograde process within the dorsal root ganglia 
neurons and a degeneration of gracile tracts of spinal cord (mostly upper 
thoracic or cervical cord segments).64 
Chronic inflammatory demyelinating polyneuropathy (CIPD) is also a 
consequence of HIV infection in the peripheral nervous system. This syndrome 
is characterized by weakness in both proximal and distal muscles of the upper 
and lower extremities. Reflexes may be sluggish or absent.54,68 Finally, the 
above symptoms of disease must be differentiated from medication side effects. 
Zidovudine (formerly called azidothymidine, or AlT), and dideoxyinosine 
(DOlor ddi) are commonly used antiviral drugs that inhibit the replication of 
retroviruses, including HIV.72 The most common candidates for drug therapy 
are patients with asymptomatic and symptomatic HIV infection who have a C04 
cell count <500 cells/mm3•74,75 Side effects from AZT may include: headaches, 
insomnia, nausea, vomiting, abdominal discomfort, diarrhea, malaise, myalgia, 
rash, fever, and severe anemia.54,65,75 001, typically prescribed for patients who 
cannot tolerate AlT, has some of the same side effects; it may also cause 
sensory peripheral neuropathy in the feet and pancreatitis symptoms.54,65,75 
CHAPTER V 
SUBJECTIVE AND OBJECTIVE FINDINGS 
Despite a decade of progress in understanding the molecular virology 
and pathophysiology of the human immunodeficiency virus, the disease caused 
by infection with this retrovirus remains incurable. As increasing numbers of 
individuals have taken heed and have determined that they are, in fact, infected 
with the retrovirus, they remain baffled by the lack of effective therapies.76 
The physical therapist faces multiple challenges when providing care to 
this population. Of particular concern to physical therapists are the 
neurological, psychological, musculoskeletal, cardiovascular, cardiopulmonary, 
and nutritional effects of the disease. It is, at times, difficult to correlate specific 
clinical signs of the disease with specific pathology because HIV has an impact 
on all systems at variable rates of progression. This places the physical 
therapist squarely in the health arena and PTs may be the first care provider to 
see indications of HIV infection. 
Good patient care requires that the diagnosis of HIV infection be made 
at the earliest possible time. As with any patient, treatment should be based on 
an accurate and appropriate assessment of the symptoms and on the patient's 
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past and present medical history. The choice of treatment rests in the HIV 
knowledge base and in the manifestation and interpretation of symptoms. 
Even without evidence of gross clinical neurological symptoms or signs, 
a physical therapist should have a basic understanding of the immune system 
to recognize manifestations of the HIV disease. Pertinent information may be 
gathered during the SUBJECTIVE and OBJECTIVE phases of the evaluation. 
During the subjective information gathering client history may reveal 
symptoms of unexplained weight loss, persistent diarrhea, night sweats, 
recurrent fever, swollen glands, decreasing vision with eye pain, bleeding gums, 
mouth sores, pain on swallowing, recent onset of headaches, easy tiring, and 
irritability. There may be a loss of interest in friends and unusual activity.77-oo 
Physical signs that may be directly observed by the therapist doing an 
objective evaluation include severe dandruff and acne, skin rashes, purplish 
spots, facial warts, ill-fitting clothes from weight loss, increased tone, unsteady 
gait. Manifestations of infections that may coexist with HIV infections are 
herpes (weeping skin lesions), hepatitis B (nausea and yellow eyes), 
tuberculosis (productive cough, night sweats, and weight loss), and shingles 
(angry painful rash).77-00 
Effects on the musculoskeletal system not previously stated in this paper 
may include an array of pain syndromes, postural deficits, and decreases in 
work function capacity related to progressive weight loss and resultant fatigue.81 
Even when symptoms are lacking, motor abnormalities can almost always be 
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detected early in the course of the disease. Motor abnormalities include 
slowing of rapid successive and alternating movements of the extremities, 
impaired ocular smooth pursuits, and saccadic eye movements.68 Abnormal 
reflexes may also be present, with generalized hyperreflexia and the 
development of release signs such as snout, glabellar, and grasp 
responses.68,80,82,83 As the disease evolves, ataxia and, subsequently, leg 
weakness limits walking. Bladder and bowel incontinence is common in the late 
stages of the disease.68,77,78,80,82,83 
In addition to obtaining musculoskeletal and neurological subjective and 
objective data, a physical therapist must also be concerned with the 
cardiovascular, pulmonary, and nutritional systems and the psychological 
implications for patients with HIV. These systems have ever changing variables 
that depend on the type of opportunistic infection(s) involved, the adequacy of 
nutrition, the level of pain, and the level of cognitive functioning.84 Further 
discussion of these systems concerning medical aspects of HIV infection is 
beyond the scope of this independent study. 
CHAPTER VI 
CONCLUSION 
Acquired Immunodeficiency Syndrome is now an epidemic in the United 
States, and all sectors of society are being affected. The care of HIV/AIDS 
infected patients is demanding. Thus, raising concerns among health care 
workers about safety, competence, and care requires both high-quantity and 
high-quality of time to treat this special population. As physical therapists we 
are in key positions to identify and intervene in the changes and losses 
commonly experienced by this unique disease. 
The physical therapist is an important contributor at all stages of the 
disease. When the person with HIV develops neurologic, musculoskeletal, or 
cardiopulmonary complications as a result of AIDS, The PT provides baseline 
data about the patient's state of fitness and function through evaluations and 
treatments. Therefore, physical therapists have the opportunity to apply their 
therapeutic skills to improve function, mobility, endurance, and safety. They 
can also communicate the importance of healthy living and physical fitness and 
identify potential problems before they erode the patient's confidence and 
independence. Physical therapy can be an effective method to help meet the 
needs of this complex population. 
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HIV has altered forever the ways in which we think about and act on life 
and living. Therefore, a solid understanding of HIV pathogenesis and a general 
working knowledge of signs and symptoms of HIV/AIDS are indispensable. As 
physical therapists we face multiple challenges when providing care to patients 
with HIV disease. There is a clearly articulated responsibility to take action to 
strengthen our personal and professional character, values, and integrity. 
Furthermore, we need to become role models in health care and participate in 
the forming of the future -- namely to "influence our professional evolution 
through our own awareness." The final and most obvious reason for physical 
therapists to become more involved in HIV/AIDS health care is the clear need 
of all patients for expert, comprehensive, and efficient care. 
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